Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting

References

• Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology focused guideline update. JCO. 2016;34:381–386.
   PubMed Web of Science ®Google Scholar
• Jordan K, Gralla R, Jahn F, et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197–202.
   PubMed Web of Science ®Google Scholar
• Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. JCO. 2006;24:2932–2947.
   PubMed Web of Science ®Google Scholar
• Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19:131–140.
   PubMed Web of Science ®Google Scholar
• Ballatori E, Roila F, Ruggeri B, et al. The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer. 2007;15:31–38.
   PubMed Web of Science ®Google Scholar
• Turini M, Piovesana V, Ruffo P, et al. An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. DIC. 2015;4:1.
   Google Scholar
• Craver C, Gayle J, Balu S, et al. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ. 2011;14:87–98.
   PubMedGoogle Scholar
• The Centers for Medicare & Medicaid Services (CMS). CMS proposes hospital outpatient prospective payment changes for 2017. [cited 2018, May 11]. Available from: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-07-06.html.
   Google Scholar
• Federal Register, Volume 81, Issue 135 (July 14, 2016), 81 FR 45603.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis version 1.2018. 2018 [cited 2018, March 28]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
   Google Scholar
• Rapoport BL. Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting. CMAR. 2017;9:41–50.
   Google Scholar
• Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12:1143–1150.
   PubMed Web of Science ®Google Scholar
• O’Sullivan CC, Van Houten HK, Sangaralingham LR, et al. Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy. J Natl Compr Canc Netw. 2018;16:294–299.
   PubMed Web of Science ®Google Scholar
• Roeland E, Ruddy K, LeBlanc T, et al. Gaps in compliance with current antiemetic guidelines for highly emetogenic chemotherapy. Presented at the National Comprehensive Cancer Network; 2018; Orlando, FL.
   Google Scholar
• Fitch K, Pelizzari P, Pyenson B. Cost drivers of cancer care: a retrospective analysis of medicare and commercially insured population claim data 2004–2014. Milliman; 2016. Available from: http://www.milliman.com/uploadedFiles/insight/2016/trends-in-cancer-care.pdf.
   Google Scholar
• Market research data on file. Helsinn Therapeutics, US., April 2017.
   Google Scholar
• Gilmore JW, Peacock NW, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. JOP. 2014;10:68–74.
   PubMedGoogle Scholar
• Aykenzo (netupitant and palonestron) [package insert]. Iselin, NJ: Helsinn Therapeutics, US; 2014.
   Google Scholar
• Emend (aprepitant) [package insert]. Kenilworth, NJ: Merck & Co.; 2003.
   Google Scholar
• Aloxi (palonosetron HCL) [package insert]. Woodcliff Lake, N.J. and Lugano, Switzerland: Eisai & Helsinn Therapeutics; 2014.
   Google Scholar
• Longo F, Mansueto G, Lapadula V, et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2011;19:1159–1164.
   PubMed Web of Science ®Google Scholar
• Hingmire S, Raut N. Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens. South Asian J Cancer. 2015;4:7–10.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Cooper W, O’Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer. 2015;23:723–732.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16:1079–1089.
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–1339.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–1346.
   PubMed Web of Science ®Google Scholar
• Rashid N, Koh HA, Baca HC, et al. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. BCTT. 2016;8:173–181.
   Google Scholar
• Agency for Healthcare Research and Quality. Healthcare Resource Utilization Project. [cited 2017, June 1]. Available from: https://hcupnet.ahrq.gov/#setup.
   Google Scholar
• Smith MW, Friedman B, Karaca Z, et al. Predicting inpatient hospital payments in the United States: a retrospective analysis. BMC Health Serv Res. 2015;15:372.
   PubMed Web of Science ®Google Scholar
• Peterson C, Xu L, Florence C, et al. Professional fee ratios for US hospital discharge data. Med Care. 2015;53:840–849.
   PubMed Web of Science ®Google Scholar
• Towle EL, Barr TR, Senese JL. The National Practice Benchmark for oncology, 2014 report on 2013 data. J Oncol Pract. 2014;10:385–406.
   PubMedGoogle Scholar
• Caldwell N, Srebotnjak T, Wang T, et al. “How much will I get charged for this?” Patient charges for top ten diagnoses in the emergency department. PLoS One. 2013;8:e55491.
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318:197–198.
   PubMed Web of Science ®Google Scholar
• Restelli U, Saibene G, Nardulli P, et al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open. 2017;7:e015645.
   PubMed Web of Science ®Google Scholar
• D’Agostino P, Cawston H, Bourhis F, et al. Fixed combination netupitant and palonosetron is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the Uk. Value Health. 2015;18:A461.
   PubMed Web of Science ®Google Scholar